Literature DB >> 17244173

A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.

D C Henderson1, X Fan, P M Copeland, C P Borba, T B Daley, D D Nguyen, H Zhang, D Hayden, O Freudenreich, C Cather, A E Evins, D C Goff.   

Abstract

UNLABELLED: This study sought to examine the effectiveness of sibutramine, a weight loss agent, on clozapine-associated weight gain.
METHOD: This was a 12-week double-blind, placebo controlled, randomized trial of sibutramine for weight loss in obese clozapine-treated schizophrenia or schizoaffective disorder subjects.
RESULTS: Ten patients were enrolled into the placebo group and 11 patients into the sibutramine group. There were no significant baseline differences between the two groups on age, gender, education, ethnicity, diagnosis, weight, body mass index (BMI), and blood pressure. At week 12, there were no significant differences in changes in weight, BMI, abdominal and waist circumferences, Hba1c, fasting glucose, or cholesterol levels.
CONCLUSION: Sibutramine treatment did not show significant weight loss compared with placebo in clozapine-treated patients with schizophrenia or schizoaffective disorder. Further research with a larger sample size and longer follow-up duration is warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17244173     DOI: 10.1111/j.1600-0447.2006.00855.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  18 in total

Review 1.  Management of antipsychotic-related weight gain.

Authors:  Lawrence Maayan; Christoph U Correll
Journal:  Expert Rev Neurother       Date:  2010-07       Impact factor: 4.618

Review 2.  Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.

Authors:  Lawrence Maayan; Julia Vakhrusheva; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

3.  Interventions for the metabolic syndrome in schizophrenia: a review.

Authors:  Evangelos Papanastasiou
Journal:  Ther Adv Endocrinol Metab       Date:  2012-10       Impact factor: 3.565

Review 4.  Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.

Authors:  Yuya Mizuno; Takefumi Suzuki; Atsuo Nakagawa; Kazunari Yoshida; Masaru Mimura; Walter Wolfgang Fleischhacker; Hiroyuki Uchida
Journal:  Schizophr Bull       Date:  2014-03-17       Impact factor: 9.306

Review 5.  Treatment of clozapine-associated weight gain: a systematic review.

Authors:  Z Whitney; R M Procyshyn; D H Fredrikson; A M Barr
Journal:  Eur J Clin Pharmacol       Date:  2015-01-28       Impact factor: 2.953

6.  Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.

Authors:  Jess G Fiedorowicz; Del D Miller; Jeffrey R Bishop; Chadi A Calarge; Vicki L Ellingrod; William G Haynes
Journal:  Curr Psychiatry Rev       Date:  2012-02-01

Review 7.  Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.

Authors:  Chaya G Bhuvaneswar; Ross J Baldessarini; Veronica L Harsh; Jonathan E Alpert
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

Review 8.  Polypharmacy for schizophrenia.

Authors:  Jacob Ballon; T Scott Stroup
Journal:  Curr Opin Psychiatry       Date:  2013-03       Impact factor: 4.741

Review 9.  Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.

Authors:  Emma E McGinty; Julia Baller; Susan T Azrin; Denise Juliano-Bult; Gail L Daumit
Journal:  Schizophr Bull       Date:  2015-07-28       Impact factor: 9.306

Review 10.  Pharmacological management of atypical antipsychotic-induced weight gain.

Authors:  Trino Baptista; Yamily ElFakih; Euderruh Uzcátegui; Ignacio Sandia; Eduardo Tálamo; Enma Araujo de Baptista; Serge Beaulieu
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.